| Followers | 129 |
| Posts | 2150 |
| Boards Moderated | 1 |
| Alias Born | 12/27/2007 |
Monday, June 24, 2019 10:57:25 AM
(ETON)..Market Cap $133 M / 2 FDA decisions imminent for attractive products on July 11 and next one on October 21 / HUGE late stage pipeline with multiple milestones in near-term milestones /undiscovered Ultra low float stock = Potential 1000% GEM
Eton Pharma (ETON)
Market-cap: $130,7 Million
Cash: $19,5 Million
Price: $7,42
Shares Out: 17,6 Million
Presentation May 2019
insert-text-here
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
Largest Shareholders
Harrow Health, Inc...3,500,000
Peter A. Appel...1,249,329 ´
Sean Brynjelsen, MBA...1,034,940
Mark L. Baum...794,745
Charles J. Casamento, MBA...60,420
Paul V. Maier, MBA...59,745
Norbert G. Riedel, PhD ...59,745
Wilson W. Troutman, CPA...5,000
https://thefly.com/landingPageNews.php?id=2925035&headline=ETON-Eton-Pharmaceuticals-analyst-commentary-
Eton Pharmaceuticals price target raised to $18 from $15 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $18 from $15 after the company in-licensed ET-105, a patent-pending formulation of lamotrigine designed to be delivered to patients as an oral liquid, from the privately-held Aucta Pharmaceuticals. The analyst believes the in-licensing of ET-105 meaningfully expands Eton's "stable" of neurology-focused product candidates. He reiterates a Buy rating on the shares.
Eton Pharma (ETON)
Market-cap: $130,7 Million
Cash: $19,5 Million
Price: $7,42
Shares Out: 17,6 Million
Presentation May 2019
insert-text-here
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
Largest Shareholders
Harrow Health, Inc...3,500,000
Peter A. Appel...1,249,329 ´
Sean Brynjelsen, MBA...1,034,940
Mark L. Baum...794,745
Charles J. Casamento, MBA...60,420
Paul V. Maier, MBA...59,745
Norbert G. Riedel, PhD ...59,745
Wilson W. Troutman, CPA...5,000
https://thefly.com/landingPageNews.php?id=2925035&headline=ETON-Eton-Pharmaceuticals-analyst-commentary-
Eton Pharmaceuticals price target raised to $18 from $15 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $18 from $15 after the company in-licensed ET-105, a patent-pending formulation of lamotrigine designed to be delivered to patients as an oral liquid, from the privately-held Aucta Pharmaceuticals. The analyst believes the in-licensing of ET-105 meaningfully expands Eton's "stable" of neurology-focused product candidates. He reiterates a Buy rating on the shares.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
